Printer Friendly

PROCYTE'S PHASE II DIABETIC FOOT ULCER RESULTS PRESENTED AT AMERICAN DIABETES ASSOCIATION ANNUAL MEETING

 KIRKLAND, Wash., June 15 /PRNewswire/ -- ProCyte Corp. (NASDAQ-NMS: PRCY) announced today that results of its Phase II study of investigational Iamin to treat chronic foot wounds in diabetic patients were presented at the annual meeting of the American Diabetes Association (ADA) in Las Vegas, Nev., June 12-14.
 The conference marked the first national medical association presentation of ProCyte's multicenter placebo-controlled Phase II clinical results in which investigational Iamin was used to treat diabetic plantar ulcers. Dr. Lee Sanders presented the clinical study results at the conference. The study results, which were disclosed earlier this year, provide statistical evidence that Iamin significantly increased the rate of wound closure in large diabetic plantar ulcers.
 ProCyte's Phase II Iamin results also showed that Iamin treatment significantly decreased the wound infection rate in diabetic plantar ulcers. The company reported earlier that treatment of all diabetic plantar ulcers with 2 percent Iamin led to a mean percent healed of 73 percent, compared to 10 percent for the placebo group. Over 50 percent of the large plantar ulcers treated with drug healed to 98 percent or greater, compared to 6 percent of the placebo-treated group. The safety profile of Iamin in the Phase II study was excellent.
 Sanders is chief of the Podiatry Section of the Veterans Administration Medical Center, Lebanon, Penn. Sanders is the chair- elect of the ADA Council on Foot Care and has published extensively on complications related to the diabetic foot. He was a clinical investigator in the Phase II study and is also one of the clinical investigators in ProCyte's Phase III clinical trial currently in progress.
 Industry sources estimate that 1.6 million diabetic patients may suffer from chronic wounds which occur predominantly on the lower limbs due to loss of circulation. Chronic wounds of the lower limb are the leading cause of hospital admissions for diabetics in this country. The majority of diabetic ulcers are plantar, which occur on the sole of the foot, and an estimated 60,000 amputations are performed annually in the United States as a result of these severe wounds.
 ProCyte's Iamin wound-healing drug candidate is a peptide-copper compound. ProCyte scientists have pioneered the use of small chains of amino acids -- known as peptides -- to deliver copper to compromised systems in the body. The body has a number of enzyme systems which are known to require copper in order to function. In certain disease conditions, such as diabetes, copper is either not present at the wound site or is not utilized properly by the body due to its compromised state. ProCyte's peptide-copper delivery system allows for the successful incorporation of copper into the body where the copper is required to activate a number of biological actions, such as wound repair.
 ProCyte Corp. is the leading developer of peptide-copper compounds for applications in wound healing and tissue repair. In addition to clinical testing for diabetic ulcers, these cost-effective therapeutic agents are being tested for treatment of inflammatory bowel disease and prevention of hair loss.
 -0- 6/15/93
 /CONTACT: Dr. Leonard Patt, director of Research, or Joseph Ashley, president and chief executive officer, of ProCyte, 206-820-4548/
 (PRCY)


CO: ProCyte Corp.; American Diabetes Association ST: Washington IN: MTC SU:

GH-SW -- SE001 -- 1946 06/15/93 08:31 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 15, 1993
Words:541
Previous Article:MAGMA COPPER ANNOUNCES BLM TO CONDUCT ENVIRONMENTAL IMPACT STATEMENT ON ROBINSON PROJECT
Next Article:NORDSTROM TEAMS WITH FACONNABLE TO OPEN NEW YORK STORE
Topics:


Related Articles
PROCYTE SCIENTISTS DISCOVER NEW COPPER-BASED THERAPEUTICS
PROCYTE CORPORATION ANNOUNCES HOLD ON WOUND STUDIES
PROCYTE ANNOUNCES FDA APPROVAL TO IMMEDIATELY RESUME PHASE III WOUND STUDIES
PROCYTE COMPLETES ENROLLMENT FOR FIRST PHASE III PIVOTAL WOUND HEALING STUDY
PROCYTE PRESENTS NOVEL PROCESSES FOR PEPTIDE MANUFACTURE
PROCYTE COMPLETES PHASE III WOUND HEALING CLINICAL TRIALS
PIMAGEDINE TESTING BEGINS IN TYPE II DIABETICS WITH KIDNEY DISEASE
ProCyte Receives Clearance to Commence Wound Healing Clinical Trial in England
Oncogene Science Announces Start Of Phase II Clinical Trials For Impaired Wound Healing

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters